Af­ter years of de­lay, BeiGene fi­nal­ly lands FDA ap­proval for its PD-1 drug

BeiGene has won the first FDA ap­proval for its PD-1 in­hibitor, mark­ing a hard-earned mile­stone af­ter a wind­ing reg­u­la­to­ry jour­ney that be­gan two and a half years ago.

Tevim­bra, the brand name for the an­ti­body al­so known as tislelizum­ab, will be avail­able in the US in the sec­ond half of 2024, BeiGene said in a press re­lease. It is cleared to treat metasta­t­ic esophageal squa­mous cell car­ci­no­ma (ES­CC) af­ter pri­or chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER